CN105194655A - Therapeutic method of neonatal bacterial infective encephalitis - Google Patents
Therapeutic method of neonatal bacterial infective encephalitis Download PDFInfo
- Publication number
- CN105194655A CN105194655A CN201510682494.0A CN201510682494A CN105194655A CN 105194655 A CN105194655 A CN 105194655A CN 201510682494 A CN201510682494 A CN 201510682494A CN 105194655 A CN105194655 A CN 105194655A
- Authority
- CN
- China
- Prior art keywords
- encephalitis
- therapeutic method
- cells
- present
- neonates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a therapeutic method of neonatal bacterial infective encephalitis. The therapeutic method comprises the step of applying a composition containing at least one type of interleukin 6 (IL-6) to a child suffering from bacterial infective encephalitis. The IL-6 provided by the invention is a pro-inflammatory factor generated by various types of cells in vivo such as mononuclear macrophages, T/B lymphocytes, vascular endothelial cells and smooth muscle cells, is located in a central position in an inflammation cascade reaction, can take various biological effects through an intracellular signal transduction pathway after being bonded with a receptor, and has the functions of resisting infection, stimulating inflammatory cells to grow, promote cell differentiation, and accelerating acute phase protein synthesis.
Description
Technical field
The present invention relates to medical field, be specially a kind of Therapeutic Method of neonates with bacterial infections encephalitis.
Background technology
At present, bacterial meningitis is the infectious disease that central nervous system is serious, is grown up common, and child patient is especially many.Many antibacterials all can cause primary disease, and wherein person caused by meningococcus is maximum, are followed successively by hemophilus influenza, streptococcus pneumoniae, escherichia coli and other Grain-positive bacillus, staphylococcus, Lee department too Seedling, anaerobe etc.
And epidemic cerebrospinal meningitis is the purulent meningitis caused by meningococcus.Pathogenic bacterium invade blood circulation by nasopharynx part, form septicemia, are finally confined to meninges and membrane of spinal cord, form suppurative meninges pathological changes.Cardinal symptom performance has the meningeal irritation signs such as heating, headache, vomiting, skin petechia and stiffness of the neck.Cerebrospinal fluid is suppurative change.The state of an illness of epidemic cerebrospinal meningitis is complicated and changeable, and weight differs, and generally can have three kinds of clinical manifestations, i.e. plain edition, fulminant type and chronic septicemia type.Plain edition accounts for whole patient's about 90%, can be divided into upper respiratory tract infection phase, septicemia phase and meningitis phase three classes by its evolution.Meningitis phase patient Gao Re and lasting toxemia, whole body still has petechia, ecchymosis, but central nervous system disorders shape increases the weight of.Because of increased intracranial pressure patient One's head is splitting, vomiting is frequent, blood pressure can increase and pulse slows down, and often has skin allergy, keeps in dark place, manic and faint from fear.After 1-2 days, patient enters delirium comatose state, can occur breathing or circulatory failure.Evening, hair style meningitis was more common in child.
Summary of the invention
Technical problem solved by the invention is the Therapeutic Method providing a kind of neonates with bacterial infections encephalitis, to solve the shortcoming in above-mentioned background technology.
Technical problem solved by the invention realizes by the following technical solutions: a kind of Therapeutic Method of neonates with bacterial infections encephalitis, comprises and use to the child suffering from bacterial infection encephalitis the compositions comprising at least one interleukin 6 (IL-6).
In the present invention, further, Streptavidin is contained in wherein said compositions.
In the present invention, further, ampicillin is contained in wherein said compositions.
In the present invention, further, wherein said bacterial infection encephalitis is acute.
In the present invention, further, wherein said at least one anti-IL-6 antibodies is for people IL-6.
In the present invention, further, the anti-IL antibody of wherein said at least one is neutrality.
In the present invention, further, wherein said at least one anti-IL-6 antibodies is humanized.
Beneficial effect of the present invention: IL-6 is the Pro-inflammatory mediator produced as mononuclear phagocyte, T, bone-marrow-derived lymphocyte, vascular endothelial cell and smooth muscle cell etc. by various kinds of cell in body, Central Position is in cascade of response of inflammation, after itself and receptors bind, through intracellular signal transduction approach performance various biological effect, there is infection, stimulate inflammatory cell growth, promote the effect that cell differentiation and acceleration acute phase protein synthesize.
Detailed description of the invention
The technological means realized to make the present invention, creation characteristic, reach object and effect is easy to understand, below to set forth the present invention further.
A Therapeutic Method for neonates with bacterial infections encephalitis, comprises and uses to the child suffering from bacterial infection encephalitis the compositions comprising at least one interleukin 6 (IL-6).
In the present invention, further, Streptavidin is contained in wherein said compositions.
In the present invention, further, ampicillin is contained in wherein said compositions.
In the present invention, further, wherein said bacterial infection encephalitis is acute.
In the present invention, further, wherein said at least one anti-IL-6 antibodies is for people IL-6.
In the present invention, further, the anti-IL antibody of wherein said at least one is neutrality.
In the present invention, further, wherein said at least one anti-IL-6 antibodies is humanized.
More than show and describe ultimate principle of the present invention and principal character and advantage of the present invention; the technical staff of the industry should understand; the present invention is not restricted to the described embodiments; what describe in above-described embodiment and description just illustrates principle of the present invention; without departing from the spirit and scope of the present invention; the present invention also has various changes and modifications; these changes and improvements all fall in the claimed scope of the invention, and application claims protection domain is defined by appending claims and equivalent thereof.
Claims (7)
1. a Therapeutic Method for neonates with bacterial infections encephalitis, is characterized in that: comprise and use to the child suffering from bacterial infection encephalitis the compositions comprising at least one interleukin 6 (IL-6).
2. the Therapeutic Method of a kind of neonates with bacterial infections encephalitis of claim 1, is characterized in that: containing Streptavidin in wherein said compositions.
3. the Therapeutic Method of a kind of neonates with bacterial infections encephalitis of claim 1, is characterized in that: containing ampicillin in wherein said compositions.
4. the Therapeutic Method of a kind of neonates with bacterial infections encephalitis of claim 1, is characterized in that: wherein said bacterial infection encephalitis is acute.
5. the Therapeutic Method of a kind of neonates with bacterial infections encephalitis of claim 1, is characterized in that: wherein said at least one anti-IL-6 antibodies is for people IL-6.
6. the Therapeutic Method of a kind of neonates with bacterial infections encephalitis of claim 5, is characterized in that: the anti-IL antibody of wherein said at least one is neutrality.
7. the Therapeutic Method of a kind of neonates with bacterial infections encephalitis of claim 1, is characterized in that: wherein said at least one anti-IL-6 antibodies is humanized.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510682494.0A CN105194655A (en) | 2015-10-21 | 2015-10-21 | Therapeutic method of neonatal bacterial infective encephalitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510682494.0A CN105194655A (en) | 2015-10-21 | 2015-10-21 | Therapeutic method of neonatal bacterial infective encephalitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105194655A true CN105194655A (en) | 2015-12-30 |
Family
ID=54942832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510682494.0A Pending CN105194655A (en) | 2015-10-21 | 2015-10-21 | Therapeutic method of neonatal bacterial infective encephalitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105194655A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103601806A (en) * | 2012-05-23 | 2014-02-26 | 亚根-X公司 | Il-6 binding molecules |
-
2015
- 2015-10-21 CN CN201510682494.0A patent/CN105194655A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103601806A (en) * | 2012-05-23 | 2014-02-26 | 亚根-X公司 | Il-6 binding molecules |
Non-Patent Citations (2)
| Title |
|---|
| 牛俊梅等: "结核性脑膜炎脑脊液中白细胞介素-6水平及临床意义", 《现代预防医学》 * |
| 裘云庆: "婴儿和儿童细菌性脑膜炎患者中白细胞介素-6的活性", 《 国外医学(流行病学传染病学分册)》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chessa et al. | An overview of Staphylococcus epidermidis and Staphylococcus aureus with a focus on developing countries | |
| Lembke et al. | Characterization of biofilm formation by clinically relevant serotypes of group A streptococci | |
| Verherstraeten et al. | Perfringolysin O: the underrated Clostridium perfringens toxin? | |
| Kukita et al. | Staphylococcus aureus SasA is responsible for binding to the salivary agglutinin gp340, derived from human saliva | |
| UA124609C2 (en) | Indoles for use in influenza virus infection | |
| Silva et al. | Biofilm formation on biotic and abiotic surfaces in the presence of antimicrobials by Escherichia coli isolates from cases of bovine mastitis | |
| CN104435000A (en) | Application of lactic acid bacteria for treating bronchial asthma | |
| EP2369350A3 (en) | Use of precursors of tachykinins and/or their fragments in medical diagnostic | |
| Wilson | Bacterial adhesion to host tissues: mechanisms and consequences | |
| Boink et al. | Saliva-derived host defense peptides histatin1 and LL-37 increase secretion of antimicrobial skin and oral mucosa chemokine CCL20 in an IL-1α-independent manner | |
| Petricevich | Effect of Tityus serrulatus venom on cytokine production and the activity of murine macrophages | |
| WO2022100126A1 (en) | Novel use of bifidobacterium lactis bl-99 in fighting aging and improving innate immunity | |
| CN105194655A (en) | Therapeutic method of neonatal bacterial infective encephalitis | |
| Dean et al. | Current approaches to precision medicine in psychiatry: Are we just spinning our wheels? | |
| CN103467569A (en) | Short peptide for bacterium resisting, itching relieving, inflammation diminishing, swelling eliminating and scar removing, and its application | |
| Cazzolla et al. | Changes in pharyngeal aerobic microflora in oral breathers after palatal rapid expansion | |
| CN101423554B (en) | Antivariant streptococcus polypeptide and use thereof and preparation method | |
| Sarkisian et al. | Assessing efficiency of synthetic peptide-containing spray in combination therapy of chronic generalized periodontitis | |
| CN107827957B (en) | Anti- clinic multi-drug resistant bacteria small peptide | |
| CN207537632U (en) | A kind of nano-antibacterial viscose fiber yarn | |
| Killingley et al. | Pneumococcal meningitis and etanercept—chance or association? | |
| Maksudov et al. | Clinical course of inflammatory diseases of the maxillofacial region in patients with viral hepatitis b | |
| Askarian et al. | Staphylococcus aureus nasal isolates from healthy individuals cause highly variable host cell responses in vitro: The Tromsø Staph and Skin Study | |
| Hanoon et al. | Evaluation of Interleukin 8, Interleukin 2 Receptor and Serum Ferritin in 60 Patients with Beta Thalassemia Major: Relationship to Splenectomy | |
| Liang et al. | Comparative analysis of staphylococcal adhesion and internalization by epithelial cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151230 |